- Home
- TPST vs ACCS Comparison
TPST vs ACCS Comparison
Compare TPST & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | ACCS |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 13.6M |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TPST | ACCS |
|---|---|---|
| Price | $0.38 | $3.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 177.6K | 14.0K |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 139.36 |
| EPS | N/A | ★ N/A |
| Revenue | $295,000.00 | ★ $22,619,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $3.21 |
| 52 Week High | $9.75 | $11.34 |
Technical Indicators
Market Signals| Indicator | TPST | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 26.93 | 35.49 |
| Support Level | N/A | $3.21 |
| Resistance Level | $0.56 | $5.11 |
| Average True Range (ATR) | 0.05 | 0.33 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 20.00 | 37.11 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.